Tech & Science: search at Novartis due to possible patent abuse

Drug that could extend lives of prostate cancer patients approved

  Drug that could extend lives of prostate cancer patients approved The intravenous drug Lutetium (177Lu) vipivotide tetraxetan has been given the green light by the Medicines and Healthcare products Regulatory Agency. It is hoped a decision on whether it will be rolled out on the NHS, by the watchdog the National Institute for Health and Care Excellence, will come later this year.

at the Swiss pharmaceutical company Novartis has been searched for. The Competition Commission (WEKO) has suspected the company that has abused a patent. The WEKO did not name the company in its message by name , but Novartis confirmed the process itself.

Beim Schweizer Pharmakonzern Novartis hat es eine Hausdurchsuchung gegeben. © Patrick Seeger/dpa The Swiss pharmaceutical company Novartis has had a house search.

The WEKO according to its own statements examines whether Novartis has used a so -called blocking patent. Such a patent is not used by a patent owner, but should only protect your own production from competition. In this case, she worked with the European Commission, the Weko said.

Novartis rejected the suspicion. "The company is confident to clarify the legitimacy of its position and cooperates with the authority without restrictions," said it.

Ranked! The 10 best players in Ligue 1 right now .
Ligue 1 has more stars than ever before – but who's the top dog in French football?

See also